The Relationship of Receptor Actions of Dopamine Agonists to Their Clinical Effects

  • Leon I. Goldberg
Part of the New Horizons in Therapeutics book series (NHTH)


We have subdivided dopamine (DA) receptors by differences in activity and potency of agonists and by demonstration of specific antagonism. The responses we have utilized can be measured in the human. Accordingly, if the subdivision is valid, the data should be useful for clinical studies.


Dopamine Receptor Dopamine Agonist Renal Blood Flow Systemic Vascular Resistance Sodium Excretion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agid, Y., Pollak, P., Bonnet, A. M., Signoret, J. L., and Lhermitte, F., 1979, Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson’s disease, Lancet 1:570–572.PubMedCrossRefGoogle Scholar
  2. Bello-Reuss, E., Higashi, Y., and Kaneda, Y., 1982, Dopamine decreases fluid reabsorption in straight portions of rabbit proximal tubule, Am. J. Physiol. 242:F634–F640.PubMedGoogle Scholar
  3. Buylaert, W. A., Willems, J. L., and Bogaert, M. G., 1978, The receptor mediating the apomorphine vasodilatation in the hindleg of the dog, J. Pharm. Pharmacol. 30:113–115.CrossRefGoogle Scholar
  4. Carey, R. M., Townsend, L. H., Rose, C. E., Jr., Kaiser, D. L., Lindsay, C. C, and Ragsdale, N. V., 1983, The specific dopamine agonist, SK&F 82526-J, increases renal blood flow and lowers blood pressure in essential hypertension, Clin. Res. 31:487A.Google Scholar
  5. Dei Cas, L., Bolognesi, R., Cucchini, F., Fappani, A., Riva, S., and Visioli, 0., 1983, Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy, J. Cardiovasc. Pharmacol. 5:249–253.PubMedCrossRefGoogle Scholar
  6. Dolak, T. M., and Goldberg, L. I., 1981, Renal blood flow and dopaminergic agonists, Annu. Rep. Med. Chem. 16:103–111.CrossRefGoogle Scholar
  7. Fennell, W. H., Kohli, J. D., and Goldberg, L. I., 1980, Hypotensive effects of N-N-di-n-propyl dopamine in the anesthetized dog: Comparison with sodium nitroprusside, J. Cardiovasc. Pharmacol. 2:247–255.PubMedCrossRefGoogle Scholar
  8. Fennell, W. H., Taylor, A. A., Young, J. B., Brandon, T. A., Ginos, J. Z., Goldberg, L. I., and Mitchell, J. R., 1983, Propylbutyldopamine: Hemodynamic effects in conscious dogs, normal human volunteers, and patients with heart failure, Circulation 67:829–836.PubMedCrossRefGoogle Scholar
  9. Finlay, G. D., Whitsett, T. L., Cucinell, E. A., and Goldberg, L. I., 1971, Augmentation of sodium and potassium excretion, glomerular filtration rate and renal plasma flow by levodopa, N. Engl. J. Med. 284:865–870.PubMedCrossRefGoogle Scholar
  10. Fluckiger, E., Vigouret, J. M., and Wagner, H. R., 1978, Ergot Compounds and prolactin secretion, in: Progress in Prolactin Physiology and Pathology (C. Robyn and M. Harter, eds.), Elsevier/North-Holland Biomedical Press, Amsterdam, pp. 383–396.Google Scholar
  11. Francis, G. S., Parks, R., and Cohn, J. N., 1983, The effects of bromocriptine in patients with congestive heart failure, Amer. Heart J. 106:100–106.PubMedCrossRefGoogle Scholar
  12. Glock, D., Kohli, J. D., and Goldberg, L. I., 1982, Domperidone: A potent and highly selective DA2 peripheral dopamine receptor antagonist, Fed. Proc. 41:1651.Google Scholar
  13. Goldberg, L. I., 1972, Cardiovascular and renal actions of dopamine: Potential clinical applications, Pharmacol. Rev. 24:1–29.PubMedGoogle Scholar
  14. Goldberg, L. I., 1974, Dopamine: Clinical uses of an endogenous catecholamine, N. Engl. J. Med. 291:707–710.PubMedCrossRefGoogle Scholar
  15. Goldberg, L. I., and Kohli, J. D., 1979, Peripheral pre-and post-synaptic dopamine receptors: Are they different from dopamine receptors in the central nervous system?, Commun. Psychopharmacol. 3:447–456.PubMedGoogle Scholar
  16. Goldberg, L. I., and Kohli, J. D., 1981, Agonists and antagonists of peripheral pre-and post-synaptic dopamine receptors: Clinical implications, in: Apomorphine and other Dopaminomimetics, Volume 1, Basic Pharmacology (G. L. Gessa and G. U. Corsini, eds.), Raven Press, New York, pp. 273–284.Google Scholar
  17. Goldberg, L. I., and Kohli, J. D., 1982, Peripheral post-synaptic dopamine (DA1) receptors, in: Advances in the Biosciences, Volume 37 Advances in Dopamine Research (M. Kohsaka, T. Shohmori, Y. Tsukada, G. N. Woodruff, eds.), Pergamon Press, Oxford, pp. 41–49.Google Scholar
  18. Goldberg, L. I., and Weder, A. B., 1980, Connections between endogenous dopamine, dopamine receptors, and sodium excretion: Evidences and hypotheses, in: Recent Advances in Clinical Pharmacology (P. Turner and D. G. Shand, eds.), Churchill Livingstone, Edinburgh, pp. 149–166.Google Scholar
  19. Goldberg, L. I., McDonald, R. H., Jr., and Zimmerman, A. M., 1963, Sodium diuresis produced by dopamine in patients with congestive heart failure, N. Engl. J. Med. 269:1060–1064.PubMedCrossRefGoogle Scholar
  20. Goldberg, L. I., Hsieh, Y. Y., and Resnekov, L., 1977, Newer catecholamines for treatment of heart failure and shock. An update on dopamine and a first look at dobutamine, Prog. Cardiovasc. Dis. 4:327–340.CrossRefGoogle Scholar
  21. Goldberg, L. L, Volkman, P. H., and Kohli, J. D., 1978, A comparison of the vascular dopamine receptor with other dopamine receptors, Annu. Rev. Pharmacol. Toxicol. 18:57–79.PubMedCrossRefGoogle Scholar
  22. Goldberg, L. I., Glock, D., Kohli, J. D., and Barnett, A., 1984, Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH23390. Hypertension, (in press).Google Scholar
  23. Hahn, R. A., Wardell, J. R., Jr., Sarau, H. M., and Ridley, P. T., 1982, Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist, J. Pharmacol. Exp. Ther. 223:305–313.PubMedGoogle Scholar
  24. Henderson, L S., Beattie, T. J., and Kennedy, A. C, 1980, Dopamine hydrochloride in oligurie states, Lancet 2:827–829.PubMedCrossRefGoogle Scholar
  25. Horwitz, D., Fox, S. M., and Goldberg, L. I., 1962, Effects of dopamine in man, Circ. Res. 10:237–243.PubMedCrossRefGoogle Scholar
  26. Judy, W. V., Watanabe, A. M., Henry, D. P., Besch, H. R., Jr., and Aprison, B., 1978, Effect of L-dopa on sympathetic nerve activity and blood pressure in the spontaneously hypertensive rat, Circ. Res. 43:24–28.PubMedCrossRefGoogle Scholar
  27. Kikuchi, K., Miyama, A., Nakao, T., Takigami, Y., Kondo, A., Mito, T., Ura, N., Tsuzuki, M., and Iimura, O., 1982, Hemodynamic and natriuretic responses to intravenous infusion of dopamine in patients with essential hypertension, Jpn. Circ. J. 46:486–493.PubMedCrossRefGoogle Scholar
  28. Kohli, J. D., Glock, D., and Goldberg, L. I., 1982, Differential antagonism of postsynaptic (DA1) and presynaptic (DA2) peripheral dopamine receptors by substituted benzamides, in: The Benzamides: Pharmacology, Neurobiology, and Clinical Aspects (J. Rotrosen and M. Stanley, eds.), Raven Press, New York, pp. 97–108.Google Scholar
  29. Kohli, J. D., Glock, D., and Goldberg, L. I., 1983, Selective DA2 versus DA1 antagonist activity of domperidone in the periphery, Eur. J. Pharmacol. 89:137–141.PubMedCrossRefGoogle Scholar
  30. Kohli, J. D., Goldberg, L. I., Volkman, P. H., and Cannon, J. G., 1978, N,N-Di-n-propyl dopamine: A qualitatively different dopamine vascular agonist, J. Pharmacol. Exp. Ther. 207:16–22.PubMedGoogle Scholar
  31. Kohli, J. D., Weder, A. B., Goldberg, L. I., and Ginos, J. Z., 1980, Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors, J. Pharmacol. Exp. Ther. 213:370–374.PubMedGoogle Scholar
  32. Laubie, M., and Schmitt, H., 1978, Inhibitory effects of piribedil on adrenergic neurotransmission, Eur. J. Pharmacol. 52:99–107.PubMedCrossRefGoogle Scholar
  33. LeBlanc, H., Lachelin, G. C. L., Abu-Fadil, S., and Yen, S. S. C, 1976, Effects of dopamine infusion on pituitary hormone secretion in humans, J. Clin. Endocrinol. Metab. 43:668–674.PubMedCrossRefGoogle Scholar
  34. Lokhandwala, M. F., and Barrett, R. J., 1982, Cardiovascular dopamine receptors: Physiological, pharmacological and therapeutic implications, J. Autonom. Pharmacol. 3:189–215.CrossRefGoogle Scholar
  35. MacCannell, K. L., McNay, J. L., Meyer, M. B., and Goldberg, L. L, 1966, The use of dopamine in the treatment of hypotension and shock, N. Engl. J. Med. 275:1389–1398.PubMedCrossRefGoogle Scholar
  36. MacLeod, R. M., Kumura, H., and Login, I., 1976, Inhibition of prolactin secretion by dopamine and piribedil (ET-495), in: Growth Hormones and Related Peptides (A. Pecile and E. E. Muller, eds.), Excerpta Medica, Amsterdam, pp. 443–453.Google Scholar
  37. McDonald, R. H., Jr., Goldberg, L. I., McNay, J. L., and Tuttle, E. P., Jr., 1964, Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow, J. Clin. Invest. 43:1116–1124.PubMedCrossRefGoogle Scholar
  38. McNay, J. L., MacCannell, K. L., Meyer, M. B., and Goldberg, L. I., 1966, Hypotensive effects of dopamine in dogs and hypertensive patients after phenoxybenzamine, J. Clin. Invest. 45:1045–1046.Google Scholar
  39. Rajfer, S. I., Anton, A. H., Rowland, J., and Goldberg, L. I., 1983, Beneficial hemodynamic effects of oral levodopa in heart failure: Relationship to the generation of dopamine, Clin. Res. 31:526A.Google Scholar
  40. Sowers, J. R., Sollars, E. G., Tuck, M. L., and Asp, N. D., 1980, Dopaminergic modulation of renin activity and aldosterone and prolactin secretion in the spontaneously hypertensive rat (40923), Proc. Soc. Exp. Biol. Med. 164:598–603.PubMedGoogle Scholar
  41. Sowers, J. R., Nyby, M., and Jasberg, K., 1982, Dopaminergic control of prolactin and blood pressure: Altered control in essential hypertension, Hypertension 4:431–437.PubMedCrossRefGoogle Scholar
  42. Stefoni, S., Docci, D., Mosconi, G., Coli, L., and Prandini, R., 1982, Longterm treatment of chronic renal insufficiency by ibopamine (SB 7505), a new orally active dopamine related drug, Clin. Nephrol. 18:168–173.PubMedGoogle Scholar
  43. Stote, R. M., Dubb, J. W., Familiar, R. G., Erb, B. B., and Alexander, F., 1983, A new oral renal vasodilator, fenoldopam, Clin. Pharmacol. & Therap. 34:309–315.CrossRefGoogle Scholar
  44. Stumpe, K. O., Kolloch, R., Higuchi, M., Kurck, F., and Vetter, H., 1977, Hyperprolactinemia and antihypertensive effect of bromocriptine in essential hypertension, Lancet,2:211–214.PubMedCrossRefGoogle Scholar
  45. Taylor, A. A., Fennell, W. H., and Mitchell, J. R., 1982, Propylbutyldopamine increases renal blood flow and decreases blood pressure in man by activation of DA1 and DA2 dopamine receptors, Clin. Res. 30:259A.Google Scholar
  46. Taylor, A. A., Fennell, W. H., Feldman, M. B., Brandon, T. A., Ginos, J. Z., and Mitchell, J. R., 1983, Activation of peripheral dopamine presynaptic receptors lowers blood pressure and heart rate in dogs, Hypertension 5:226–234.PubMedCrossRefGoogle Scholar
  47. Ventura, H. O., Messerli, F. H., Oigman, W., Dunn, F. G., Kobrin, I., and Fröhlich, E. D., 1983, Immediate hemodynamic effects of SK&F 82526J—A dopamine agonist—in hypertension, Circulation 68:111–46, #181.Google Scholar
  48. Whitsett, T. L., and Goldberg, L. I., 1972, Effects of levodopa on systolic preejection period, blood pressure and heart rate during acute and chronic treatment of Parkinson’s disease, Circulation 45:97–106.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Leon I. Goldberg
    • 1
  1. 1.Committee on Clinical Pharmacology, Departments of Pharmacological and Physiological Sciences and MedicineThe University of ChicagoChicagoUSA

Personalised recommendations